Anti-PD1 Antibody (A283186)

Anti-PD1 Antibody

Rabbit polyclonal antibody to PD1.

This antibody recognises CD279, a co-stimulatory molecule also known as programmed cell death-1 (PD-1). CD279 is a single-pass type 1 membrane protein belonging to the CD28 family, and functions mainly as a negative regulator of T-cell activation. CD279 has two specific ligands; CD274 (PD-L1) and CD273 (PD-L2), and their interaction is key in the balance between stimulatory and inhibitory signals needed for effective immune responses to microbes and self-tolerance. CD279 is inducibly expressed by T-cells, B-cells, NK-T-cells and monocytes upon activation.Loss of CD279 function has been associated with a number of autoimmune diseases, including rheumatoid arthritis, type I diabetes and ankylosing spondylitis. CD279 could be targeted therapeutically in the treatment of HIV infection to reduce T-cell exhaustion.

WB, IHC-P

IHC-P 1: 2.5 µg/ml, WB: 0.5 - 1 µg/ml

Human, Mouse

A peptide corresponding to 16 amino acids near the C-terminus of human CD279.

Rabbit

Polyclonal

IgG

1 mg/ml

Liquid

Supplied in Phosphate Buffered Saline with 0.02% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Rabbit anti Human CD279 antibody detects CD279, a co-stimulatory molecule also known as programmed cell death-1 (PD-1). CD279 is a single-pass type 1 membrane protein belonging to the CD28 family, and functions mainly as a negative regulator of T-cell activation. CD279 has two specific ligands; CD274 (PD-L1) and CD273 (PD-L2), and their interaction is key in the balance between stimulatory and inhibitory signals needed for effective immune responses to microbes and self-tolerance. CD279 is inducibly expressed by T-cells, B-cells, NK-T-cells and monocytes upon activation. Loss of CD279 function has been associated with a number of autoimmune diseases, including rheumatoid arthritis, type I diabetes and ankylosing spondylitis. CD279 could be targeted therapeutically in the treatment of HIV infection to reduce T-cell exhaustion (Freeman et al. 2006).

CD279, CD279 antigen, hPD 1, hPD l, hPD-1, hSLE1, PD 1, PD-1, PDCD 1, PDCD1, PDCD1_HUMAN, Programmed cell death 1, Programmed cell death 1 protein, Programmed cell death protein 1, Protein PD 1, Protein PD-1, SLEB2, Systemic lupus erythematosus susceptibility 2